Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws
Publication Date
10-2023
Document Type
Article
Publication Title
Biotechnology Law Report
Volume
42
Issue
5
Recommended Citation
Christopher M. Holman,
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws,
42
Biotechnology Law Report
230
(2023).
Available at:
https://irlaw.umkc.edu/faculty_works/970
COinS